Buserelin Dosing & Reconstitution Guide

Buserelin can be administered via various routes, including intranasal spray, subcutaneous injection, or subcutaneous depot implant. The frequency of administration varies based on the specific clinical context. For instance, in the management of prostate cancer, intranasal dosing may occur three times daily, amounting to a total of 1200 mcg per day (400 mcg TID). In contrast, for in vitro fertilization (IVF) protocols, the nasal spray might be utilized 2 to 4 times daily, with initial subcutaneous injections typically set at 200-500 mcg TID before transitioning to a depot formulation every 2 to 3 months. These dosing regimens are derived from clinical studies and should be interpreted within the context of their respective research frameworks.

Research indicates that Buserelin exhibits a delayed onset of action, with hormonal suppression typically observed within 2 to 4 weeks following administration. Peak plasma concentrations for the intranasal route are reached approximately 1 to 2 hours post-administration, while the drug's half-life is approximately 80 minutes. The timeline for achieving notable results, particularly regarding hormonal suppression, aligns with the 2 to 4-week window. It is also important to consider a washout period of 2 to 4 weeks, which may be necessary to assess the drug's effects fully and to prepare for subsequent treatment phases.

The storage conditions for Buserelin vary depending on its formulation. For the lyophilized form, specific guidelines for storage do not apply to the nasal spray, which is supplied as a solution. Once reconstituted, it is recommended that Buserelin be stored below 25 °C, avoiding any exposure to freezing temperatures, particularly for the nasal spray formulation. Proper storage is crucial to maintain the integrity of the compound and ensure its suitability for research purposes.

The safety profile of Buserelin includes common side effects such as hot flashes, which occur with a frequency comparable to other GnRH agonists. Additional reported effects may include decreased libido, sexual dysfunction, headaches, and mood changes. It is essential to recognize that Buserelin is contraindicated in certain populations, including pregnant individuals due to the potential for fetal harm, as well as patients with hormone-dependent tumors outside of prostate or breast cancer contexts. Furthermore, undiagnosed vaginal bleeding represents another contraindication to the use of this compound, highlighting the need for thorough patient evaluation in research settings.